Tag: opioid epidemic

Activists Renew Effort To Use Opioid Settlement Funds To Study Ibogaine For Addiction In Ohio After Kentucky Plan Falls Through

Psychedelic medicine proponents are redirecting their efforts to use millions in opioid-related state settlement money for ibogaine research from Kentucky to Ohio.

The original plan to use $42 million from Kentucky’s opioid settlement fund for psychedelics research fell through late last year after the state’s new attorney general replaced then-Kentucky Opioid Commission Chairman Bryan Hubbard, who was spearheading the ibogaine initiative, with a former Drug Enforcement Administration (DEA) official.

Now Hubbard has joined ResultsOHIO, a division of the Ohio Treasurer’s Office, where he will be partnering with the Reaching Everyone in Distress (REID) Foundation in hopes of securing a portion of that state’s opioid settlement funds to promote psychedelics clinical trials for substance misuse treatment.

“I’m honored to work with the REID Foundation and the people of Ohio to bring hope and healing to veterans and families being torn apart by the opioid crisis,” Hubbard said in a press release. “The development of ibogaine as a treatment option for opioid-dependent individuals is a moral imperative.”

A Kentucky commission focused on opioid overdose abatement held several meetings last year to go over the ibogaine initiative that’s since fizzled out in that state under the new attorney general. Members heard testimony from military veterans, parents, psychologists and other advocates—including former Texas Gov. Rick Perry (R)—about the therapeutic potential of the psychedelic.

Like Kentucky, Ohio has been hard hit by the opioid overdose crisis. And under the settlement agreement, the state is expected to receive about $1 billion that could be used for various programs and services to help mitigate the public health issue.

The plan for the ibogaine effort is to seek funding for the research through a public-private partnership, while also exploring the creation of a specific program under ResultsOHIO to facilitate the partial settlement distribution, Psychedelic Alpha reported.

Keep reading

Did Decriminalization Boost Drug Deaths in Oregon?

Oregon is considering legislation that would recriminalize low-level drug possession, reversing a landmark reform that voters approved in 2020. Although critics of that ballot initiative, Measure 110, cite escalating drug-related deaths, decriminalization is not responsible for that trend.

Opioid overdose fatalities have been rising nationwide for more than two decades. That trend was accelerated by the emergence of illicit fentanyl as a heroin booster and substitute, a development that hit Western states after it was apparent in other parts of the country.

“Overdose mortality rates started climbing in [the] Northeast, South, and Midwest in 2014 as the percent of deaths related to fentanyl increased,” RTI International epidemiologist Alex H. Kral and his colleagues noted at a conference in Salem, Oregon, last month. “Overdose mortality rates in Western states did not start rising until 2020, during COVID and a year after the introduction of fentanyl.”

That lag explains why Oregon has seen a sharper rise in opioid-related deaths than most of the country since 2020. But so have California, Nevada, and Washington, neighboring states where drug possession remains a crime.

Decriminalization under Measure 110 took effect in February 2021, and a 2023 Journal of Health Economics study estimated that it was associated with a 23 percent increase in “unintentional drug overdose deaths” that year. But “after adjusting for the rapid escalation of fentanyl,” Brown University public health researcher Brandon del Pozo reported at the Salem conference, “analysis found no association between [Measure 110] and fatal drug overdose rates.”

Kral and his collaborators concurred, saying “there is no evidence that increases in overdose mortality in Oregon are due to” decriminalization. That is consistent with the results of a 2023 JAMA Psychiatry study, which found “no evidence” that Measure 110 was “associated with changes in fatal drug overdose rates” during the first year.

Keep reading

Girlfriend charged with murder of former Texas judge who died of fentanyl overdose

Authorities in Texas have arrested the 35-year-old girlfriend of a former judge for allegedly supplying him with fentanyl that led to his overdose death late last year. Kami Ludwig was taken into custody on Monday and charged with the murder of 47-year-old former Associate Tarrant County Judge William Shane Nolen.

The murder charge is the result of a novel interpretation of a new law that Gov. Greg Abbott signed in June 2023 and went into effect on Sept. 1, 2023, classifying the supplying of fentanyl that results in death as murder. The law was enacted to combat the thousands of Texans who die annually from fentanyl poisoning, but appeared to primarily target drug dealers who distribute the deadly substance.

According to a news release from the Grapevine Police Department, officers at about 4:45 a.m. on Nov. 20, 2023, responded to a call regarding a deceased male — later identified as Nolen — at a residence located in the 4100 block of Mapleridge Drive. Ludwig placed the initial 911 call and identified herself to the dispatcher as Nolen’s girlfriend.

Upon arriving at the scene, first responders said they found Nolen deceased in his bedroom “with signs consistent with an opioid overdose.” Authorities on the scene said they also recovered “several” additional pills from inside the home.

Keep reading

Maine Democratic Governor And GOP Senate Leader Oppose Bill To Decriminalize Drugs And Invest In Treatment

Maine saw a reduction in the number of overdose deaths in 2023. But with hundreds upon hundreds of drug-related deaths last year, advocates and lawmakers say the state is still in the midst of a serious crisis.

In total, there were 607 confirmed or suspected overdose deaths in 2023, a 16 percent drop from the record total of 723 in 2022. Along with the 607 deaths, there were 9,047 confirmed nonfatal overdoses last year (compared to 9,760 in 2022).

“I think it’s hard to talk about this because that’s still 607 people who died last year and I don’t want to celebrate that whatsoever,” said Courtney Gary-Allen, organizing director of the Maine Recovery Advocacy Project. “That being said, there is a reduction, and I think we should be proud of the work that we’ve all collectively done on this issue.”

Gary-Allen cited investments in treatment by Gov. Janet Mills’ administration, the bipartisan consensus that substance use is a serious crisis that needs to be addressed, and the passage of the Good Samaritan law—which created enhanced protections from prosecution at the scene of an overdose to encourage people to call for help—as possible reasons for the reduction in deaths in 2023. Others have also cited the increased availability of the opioid overdose reversal naloxone.

Still, Gary-Allen said there is much more to do to address the overdose epidemic.

“I still have the faces in my head” of those who have died from drug overdoses, she said.

One proposal, backed by advocates in the recovery community and sponsored by Rep. Lydia Crafts (D-Newcastle), is to decriminalize the personal possession of illegal drugs and invest in an array of treatment options.

Supporters of the measure argue that criminalizing drug use pushes people into the shadows, making it harder for them to get help. Policing drug use and imprisoning people for substance use-related crimes also takes money away from a treatment-based approach, proponents of the bill say.

In all, policy analysts estimate the state could save around $45 million a year from not punishing people for possession of small amounts of drugs. Under the terms of the proposal, that money would then be invested into expanding what advocates say are often scant treatment options around the state.

Keep reading

A New Pain Medication Could Reinforce the Disastrous Crackdown on Prescription Opioids

Vertex Pharmaceuticals is trumpeting the results of clinical trials indicating that VX-548, its new, non-opioid analgesic, is effective at relieving post-surgical pain. While there is nothing wrong with offering patients and doctors another option for treating acute pain, the Phase 3 trials found that VX-548 was no more effective than a combination of hydrocodone and acetaminophen in relieving pain after tummy tucks and less effective for patients who had bunions removed.

As a new drug under patent, VX-548 is bound to be much more expensive than generic versions of Vicodin, and its main selling point seems to be based on a gross exaggeration of that familiar drug’s addictive potential. The introduction of VX-548 therefore could reinforce myths about the risks of prescription opioids and encourage the government’s misguided and heavy-handed crackdown on those medications.

“People who are suffering from severe pain but don’t want to risk addiction to an opioid are closer to a new option for treatment,” The Wall Street Journal reports. The Journal claims “opioids are highly addictive,” which is not true by any reasonable measure.

A 2018 BMJ study of 568,612 patients who took prescription opioids following surgery found that 5,906, or 1 percent, showed documented signs of “opioid misuse” during the course of the study, which included data from 2008 through 2016. The outcome measure that the researchers used, “opioid dependence, abuse, or overdose,” is a broad category that includes patterns of use falling short of what most people would recognize as addiction. That suggests the actual addiction rate in this study probably was less than 1 percent, although it’s not clear how much less. The authors noted that “overall rates of misuse were low.”

Estimates of addiction rates among patients who take opioids for longer periods of time tend to be higher but still lower than the phrase “highly addictive” suggests. A 2010 analysis in the Cochrane Database of Systematic Reviews found that less than 1 percent of patients taking opioids for chronic pain experienced addiction. A 2012 review in the journal Addiction likewise concluded that “opioid analgesics for chronic pain conditions are not associated with a major risk for developing dependence.”

Keep reading

Survey: Pain Patents Report That Cannabis Is “More Effective” Than Conventional Medications

Patients with chronic pain and other conditions report that cannabis is often more effective than conventional treatments, according to survey data published in the journal Frontiers in Medicine.

German researchers surveyed patients’ experiences with cannabis products. (Plant cannabis and cannabinoid treatments, such as , were legalized by prescription use in Germany in 2017; however, such products are typically only authorized when patients are unresponsive to traditional therapies.) Over 200 patients participated in the survey. Most respondents suffered from chronic pain and over two-thirds of the survey’s participants consumed cannabis flowers or plant-derived extracts.

Consistent with numerous other studies, patients reported reductions in their daily pain following cannabis therapy. Patients also said that they were less likely to be either anxious or depressed while using cannabis. Participants reported “greater satisfaction” with cannabis and said that it was “more effective” than their prior therapies. Ninety-four percent of those surveyed reported holding more positive attitudes toward cannabis following treatment. 

Keep reading

Vermont House Passes Bill To Legalize And Fund Safe Drug Consumption Sites Over Governor’s Objection

Vermont’s House of Representatives has passed a bill to create and fund overdose prevention centers in the state, part of a pilot program aimed at quelling the ongoing epidemic of drug-related deaths. It’s another attempt by lawmakers to allow the facilities following Gov. Phil Scott’s (R) veto of a 2022 measure that would have established a task force to create a plan to open the sites.

If the measure, H.72, is enacted into law, Vermont would join Rhode Island and Minnesota in authorizing the facilities, where people can use illicit drugs in a supervised environment and be connected to various support services, including treatment.

Led by Rep. Taylor Small (D) and 28 other co-sponsors, the bill in its current form would earmark $2 million to support the creation of two overdose prevention centers along with $300,000 to study the impacts of the program.

After adopting a number of amendments, the full House passed the measure on Thursday, advancing the proposal to the Senate.

“People around the country are acknowledging that old, stigmatizing approaches aren’t working, while evidence is clear overdose prevention centers save lives,” said Grey Gardner, senior policy council for the advocacy group Drug Policy Alliance (DPA), which supports the legislation.

Since 2010, Gardner noted, overdose fatalities in Vermont have climbed by nearly 500 percent.

“The priority needs to be saving lives, improving connections to care, and benefiting communities,” he said, “and that’s exactly what overdose prevention centers are proven to do.”

Among the more notable recent changes ahead of House passage, an amendment offered by Rep. Eric Maguire (R) added a local opt-in provision that would allow sites to open “only upon an affirmative vote of the legislative body of the municipality.”

Earlier House amendments to the bill doubled the funding for the sites—from $1 million to $2 million—and directed that funding to study the pilot program should come from the a state opioid abatement fund.

Even if the overdose prevention center legislation passes the Senate, where it has been referred to the Health and Welfare Committee, it still faces a possible veto from Scott.

“I just don’t think that a government entity should be in the business of enabling those who are addicted to these drugs that are illegal,” the governor said of the measure, according to WCAX.

Scott wrote in his 2022 veto message on the earlier legislation that “it seems counterintuitive to divert resources from proven harm reduction strategies to plan injection sites without clear data on the effectiveness of this approach.”

Though Rhode Island and Minnesota have state laws on the books allowing safe consumption sites, New York City became the first U.S. jurisdiction to open locally sanctioned harm reduction centers in November 2021, and officials have reported positive results saving lives.

Keep reading

West Virginia Senate President Says Marijuana Could Be Legalized To Help Curb Fentanyl Epidemic, ‘Sooner Than Later’

West Virginia’s Republican Senate president says that legalizing marijuana could help ease the state’s crush of fatal fentanyl overdoses, predicting that the policy change will come “sooner than later” but probably not in the new legislative session.

“My gut tells me it might not happen this year,” Senate President Craig Blair (R) said at a media event last week, according to West Virginia Public Broadcasting. “But you’re going to see it sooner than later, because that is a way to combat the issue.”

Data from the Centers for Disease Control and Prevention (CDC) show that West Virginia had more fatal fentanyl overdoses per capital in 2022 than any other state in the nation.

The Senate president also noted that he sees a lot of West Virginia license plates at marijuana dispensaries when he’s visiting other states, according to West Virginia watch.

Speaking to the fentanyl problem, Blair also claimed at the event that “there is a problem in the state of West Virginia when marijuana, over 70 percent of it that gets tested, has fentanyl on it.” He is supporting legislaiton that would apply the death penalty to people who sell fentanyl.

It’s not clear what data, if any, Blair was referencing with that assertion. The organization Partnership to End Addiction says there’s “no solid evidence that marijuana is being laced with fentanyl.”

House Minority Leader Sean Hornbuckle (D) also discussed his own party’s support for legalization in West Virginia.

“We’re a believer in adult-use cannabis,” he said, pointing out that policy change “polls well into the 60s” in terms of percent of voter support.

“That is something that we can have in our toolkit that can help pay for items,” he told the event’s attendees.

Keep reading

Could magic mushrooms replace oxycodone?  Ingredient found in psychedelic helps treat chronic pain by reshaping the brain, study suggests

An injection of psilocybin, the key ingredient in so-called ‘magic mushrooms,’ could offer lasting relief from chronic pain, according to new research.

A team of scientists at the University of Michigan found that rats given the psychedelic drug were significantly less sensitive to pain for weeks compared to animals who did not receive it. 

These results suggest that the drug is altering pathways in the brain, the study authors wrote.

Scientists suspect many chronic pain conditions are the result of changes to the brain and spinal cord, not just the body part that’s in pain. 

Psilocybin may modify these pathways rather than just treating the symptoms of pain.

In the new study, rats were given a small injection of formaldehyde in their foot to simulate chronic pain. 

Injections like this can lead to a month or more of hypersensitivity, even in the feet that haven’t been injected.

So, while this pain isn’t the same as a person with a back injury or other chronic pain experiences, it is one way for scientists to study long-lasting pain.

The lab animals were then given either a low-dose injection of psilocybin, a high-dose injection, or an injection of harmless salt water – a placebo to ensure the drug was responsible for the observed effects. 

The low-dose group received 1mg per kilogram of body weight, the equivalent of a microdose, while the high-dose group received 10mg per kilogram, a hallucinogenic dose. 

Keep reading

A DEFENSE-LINKED CONTRACTOR TOOK OVER A SUCCESSFUL CDC ANTI-OVERDOSE INITIATIVE. IT IMPLODED IN A DAY.

A GROUNDBREAKING Centers for Disease Control and Prevention initiative to support harm-reduction groups across the country fell apart this month after the program came under the control of a federal contractor that has done no public health work for the government.

The National Harm Reduction Technical Assistance Center, or TA Center, was founded in 2019 as a coalition of harm-reduction groups partnered with the CDC to offer training, funding, and guidance to those working to reduce overdose deaths. Its success rested on the deep experience and the trust community members had for the three main partner organizations, which included the National Alliance of State and Territorial AIDS Directors, or NASTAD; the National Harm Reduction Coalition, or NHRC; the University of Washington’s Supporting Harm Reduction Programs; and a handful of other groups.

This month, the TA Center ceased functioning as it had for more than three years: Instead of a partnership, the project would be administered as a federal contract. And the CDC gave the sole-source contract to the Florida-based firm H2 PCI, a relatively new federal contractor with close links to the defense industry and the murky world of military special operations.

H2 PCI entered negotiations with the primary partners in the center to make them subcontractors but did not send proposed subcontracts to the groups until early November. Rushed by deadlines, those talks broke down in late November, according to Laura Guzman, executive director of NHRC.

As the H2 PCI contract went into effect on December 1, the primary partner organizations that had made the TA Center a success parted ways with the project, Guzman told The Intercept.

“From the beginning, it was clear that they had zero experience in the public health field and absolutely zero experience in harm reduction,” Guzman said. “It would be really challenging to work with a contractor who has zero understanding of our world.”

Advocates fear the takeover could wash away the years of painstaking work of building up the TA Center and sever its vital connection to on-the-ground harm reduction providers, making it harder for them to serve the people who rely on them for clean needles, naloxone, and other services, according to Maya Doe-Simkins, a veteran harm reductionist who has worked closely with the program.

Keep reading